Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different ...

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

And it will likely be the first company in the sector to get there.

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while ...

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...

Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

As the $1 trln drugmaker’s smash-hit obesity treatments shrink waistlines, its ​cashflow and valuation are ​swelling. Gilead, ...

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more ...